American Association for Cancer Research

Poster Session B

Poster Session B

Wednesday, January 8 • 12:30 p.m.-2:30 p.m.

In board assignment order

  • B01   Phosphorylation of pro-oncogenic c-Src at serine-17 by protein kinase G- promotes chemoresistance/cell proliferation in human non-small cell lung cancer cells, Mary G Johlfs
  • B02   Protein Kinase C iota is required for the maintenance of a tumor-initiating cell phenotype in lung squamous cell carcinoma, Verline Justilien
  • B03   Identification of R-spondin fusions in NSCLC, Jayaprakash Karkera
  • B04, PR03   Targeting CREB-CBP transcription factor complex using small molecule inhibitors with multifunctional anticancer mechanisms, Jaseok Peter Koo
  • B05   Tissue-compatible EGFR genotyping in tumor-derived extracellular vesicles from malignant pleural effusions, Kye Young Lee
  • B06   Development of novel thiobarbituric acid derivative compounds for treatment of lung cancers, Sang Y. Lee
  • B07   Loss of LKB1 promotes CXCL8 production via NF-B and WNT signaling in human bronchial epithelial cells, Rui Li
  • B08   Triptolide has antitumor effects in lung cancer via Wnt pathway inhibition, Youqiang Li
  • B09   Multiplexed mass spectrometry-based assay to quantify translocation markers from non-small cell lung cancer (NSCLC) FFPE tissue, Wei-Li Liao
  • B10   Acquired resistance to afatinib plus cetuximab in EGFR-mutant lung adenocarcinoma may be mediated by EGFR overexpression and overcome by the mutant-specific EGFR inhibitor, AZD9291, Catherine B. Meador
  • B11   Female or male? Erroneous annotation in public lung cancer gene expression data sets, Patrick Micke
  • B12   Novel molecular mechanisms of acquired resistance to gefitinib in lung adenocarcinoma, Asuka Nakata
  • B13   Non-small cell lung cancer with double driver mutations, Atsushi Osoegawa
  • B14, PR04   Distinctive squamous cell carcinoma protein signatures, Rachel Ostroff
  • B15   Cell motility and deformability in the pathogenesis of lung cancer, Paul C. Pagano
  • B16   The effect of e-cigarette exposure on airway epithelial cell gene expression and transformation, Stacy J. Park
  • B17   Sox9 mediates Notch pathway-induced epithelial-mesenchymal transition (EMT) in lung adenocarcinoma, Sharon R. Pine
  • B18, PR05   Identification of functionally relevant off-targets of tivantinib in lung cancer, Uwe Rix
  • B19   Three-dimensional nuclear telomere organization and clinical significance in non-small cell lung cancer patients, Patrapim Sunpaweravong
  • B20   Prediction of lung cancer survival by genes in the PAM50 breast cancer panel, Jill M. Siegfried
  • B21, PR06   The neurotrophin receptor TrkB promotes lung adenocarcinoma metastasis, Kerstin Sinkevicius
  • B22   Can lung cancer with overexpression of RET-proto oncogene be a good candidate for vandetanib treatment? Mitsuhiro Sunohara
  • B23, PR07   BRG1-inactivating mutations as potential predictive markers for Aurora kinase A-targeted therapy, Vural Tagal
  • B24   A systematic search for cancer/testis antigens in lung cancer identifies VCX/Y genes expanding the repertoire of potential immunotherapeutic targets, Ayumu Taguchi
  • B25   Effect of Hsp90 inhibitor 17-DMAG on ligand-triggered resistance to alectinib in EML4-ALK NSCLC cells, Azusa Tanimoto
  • B26   Design and synthesis of furoquinoline derivatives as potential drug candidates for the treatment of lung cancers, Cherng-Chyi Tzeng
  • B27   Phenotypic plasticity and heterogeneity in small-cell lung cancer (SCLC): Novel molecular subtypes and potential for targeted therapy, Akshata Ramrao Udyavar
  • B28   Histone methylation-mediated silencing of mir-139 enhances an aggressive phenotype of non-small cell lung cancer, Kousuke Watanabe
  • B29   Ki67 proliferation index score paradoxical increase after neoadjuvant therapy in resected NSCLC, Glen J. Weiss
  • B30   Selective small molecule AXL inhibitor BGB324 overcomes acquired drug resistance in non-small cell lung carcinoma models, Katarzyna Wnuk-Lipinska
  • B31   The brain-specific metabolite N-acetylaspartate is a new biomarker for non-small cell lung cancer, Hyuntae Yoo
  • B32   The impact of PET-CT on staging, management and prognostication of small-cell lung cancer, Alona Zer
  • B33   Characterizing splicing factor mutations in lung cancers, Dennis Liang Fei
  • B34   The genomic landscape of lung adenocarcinomas in individuals without significant exposure to tobacco, William W. Lockwood
  • B35   The expression of four genes as a prognostic classifier for stage I lung adenocarcinoma in 12 independent cohorts, Aaron J Schetter
  • B36   Synthesizing new proteins from 3-dimensional spheroids, compare to 2-dimensional cell line culture, Ki-Up Kim